Why I’d sell Woodford Patient Capital Trust plc today

G A Chester explains how Woodford Patient Capital Trust plc (LON:WPCT) has morphed into a much higher-risk investment than when it was launched.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve reconsidered my position on master investor Neil Woodford’s Patient Capital Trust (LSE: WPCT), having reviewed its development since its launch in April 2015. The shares have performed poorly — they’re trading at 83p versus an IPO price of 100p — but there are more fundamental reasons why I now rate the trust a ‘sell’.

Prospectus

The trust issued a prospectus ahead of its launch and the following table summarises how Woodford expected the portfolio to look “one or two years from admission”:

Company type Characteristics Portfolio weighting
Mature Mid- and large-cap. Quoted companies. “Woodford’s high conviction blue-chip ideas.” c. 25%
Early growth “Typically quoted although may be unquoted companies.” c. 25%
Early stage “Likely to include both quoted and unquoted companies.” c. 50%

The trust appeared to offer a good balance between prudence and risk, with a decent chunk of the portfolio in liquid blue-chip stocks and even the second-tier early growth companies being “typically quoted.” While the weightings weren’t set in stone, there was a longstop on exposure to illiquid, unquoted companies, the prospectus declaring a maximum limit of 60% of net asset value (NAV) at the time of investment.

Also providing comfort on the risk front, the prospectus advised that while the trust was permitted to use gearing of up to 20% of NAV (at the time of borrowing), it “does not intend to deploy long-term gearing.”

Shaped up nicely

At the end of its first financial year (31 December 2015), it had shaped up nicely, being “substantially invested.” It held a small amount of cash and had no borrowings.

Mature companies, including FTSE 100 giants AstraZeneca, GlaxoSmithKline, Legal & General and Provident Financial, represented 30% of the portfolio. The early growth segment was at 23% and early stage at 46%. In terms of the balance of quoted and unquoted companies, the former had a weighting of 63% and the latter 36%.

A far higher risk proposition

However, the trust has morphed into a rather different animal to that envisaged in the prospectus. All its FTSE 100 holdings have been sold, the limit on unquoted companies has been increased from 60% to 80% and it’s dropped “does not intend to deploy long-term gearing” from its remit.

As of 30 November, I calculate that unquoted companies represented 78% of NAV and that Woodford had utilised £143m of a £150m overdraft facility, giving the trust gearing of 19%. The table below shows the top 10 holdings.

Company Status Market Weighting (%)
Prothena Quoted Nasdaq 11.8
Oxford Nanopore Unquoted n/a 9.3
Benevolent AI Unquoted n/a 7.1
Immunocore A Unquoted n/a 6.8
Purplebricks Quoted AIM 6.0
Proton Partners International Unquoted n/a 4.5
Autolus Unquoted n/a 4.4
Mereo Biopharma Quoted AIM 4.3
Atom Bank Unquoted n/a 4.2
Theravance Biopharma Quoted Nasdaq 3.9

The four quoted companies are all lossmaking and hardly seem to fit the prospectus mould of “Woodford’s high conviction blue-chip ideas.” Indeed, with the portfolio also stuffed to the hilt with unquoted companies (many of which require ongoing funding) and with the overdraft and gearing limit almost maxed out, the trust now looks a far higher-risk proposition than when it launched.

The shares currently trade at a discount of less than 10% to NAV. I believe the discount should be much wider and I rate the stock a ‘sell’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£3,000 in savings? Here’s how I’d use that to start earning a monthly passive income

Our writer digs into the details of how spending a few thousand pounds on dividend shares now could help him…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BP share price in the next three years

I can understand why the BP share price is low, as oil's increasingly seen as evil. But BP's a cash…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »